Clinical Trial Update: Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pasireotide LAR for silent corticotroph pituitary tumors; study is terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acth-producing Pituitary Tumor
• Pituitary Tumor

Drugs mentioned

• Pasireotide LAR (pasireotide)

Snippet

Sponsor: Columbia University | Conditions: Pituitary Tumor, ACTH-producing Pituitary Tumour | Phase 2 | Status: TERMINATED | Results posted: 2021-04-27